Praxis Precision Medicines Reports Positive Phase 3 Results for Ulixacaltamide in Essential Tremor

Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the Reddit stocks that will go to the moon. On October 16, Praxis Precision Medicines announced positive topline results for its pivotal Phase 3 Essential3 program for ulixacaltamide in essential tremor/ET. Ulixacaltamide is a differentiated, highly selective small molecule inhibitor of T-type calcium channels designed to block abnormal neuronal burst firing in the Cerebello-Thalamo-Cortical/CTC circuit.

The announcement is significant because ET is the most common movement disorder, affecting ~7 million people in the US, and current treatment options are limited in efficacy and tolerability, leading to an estimated minimum of 2 million patients actively seeking better treatment. Patients in the Essential3 program had been living with ET for an average of 30 years, underscoring the high unmet need; over 200,000 people were interested in participating in the study.

Praxis Precision Medicines Reports Positive Phase 3 Results for Ulixacaltamide in Essential Tremor

The Essential3 Phase 3 program included two simultaneously enrolled studies utilizing a decentralized, home-based design across all 50 states in the US. Praxis has submitted a pre-NDA meeting request to the FDA and plans to submit the NDA by early 2026, pending agreement with the agency.

Praxis Precision Medicines Inc. (NASDAQ:PRAX) is a clinical-stage biopharmaceutical company that develops therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance.

While we acknowledge the potential of PRAX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PRAX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.